Background {#Sec1}
==========

Rheumatoid arthritis is a systemic disorder that primarily affects the joints, but renal involvement is relatively common and clinically significant because it worsens the course and mortality of the primary disease \[[@CR1]\]. Renal involvement in rheumatoid arthritis includes secondary amyloidosis, nephrotoxicity of the drugs used for treatment, and rheumatoid nephropathy as extra-articular manifestations \[[@CR1]--[@CR5]\]. In rheumatoid nephropathies, mesangial glomerular nephritis is the most frequent histological lesion, followed by minimal change glomerulopathy, membranous glomerulopathy, and crescentic glomerular nephritis \[[@CR1], [@CR2], [@CR6]--[@CR10]\]. Crescentic glomerular nephritis is rare, and more than 50% of the patients have features of systemic vasculitis, with almost all having perinuclear antineutrophil cytoplasmic antibody positivity \[[@CR9], [@CR10]\]. Only one case of rheumatoid arthritis-associated antineutrophil cytoplasmic antibody (ANCA)-negative crescentic glomerular nephritis has been reported to date \[[@CR10]\]. We report a case of a patient with rheumatoid arthritis who presented with ANCA-negative crescentic glomerular nephritis without frank systemic vasculitis.

Case presentation {#Sec2}
=================

A 54-year-old Sri Lankan woman who had recently been diagnosed with rheumatoid arthritis presented to our hospital with worsening bilatateral leg swelling and facial puffiness of 1 month's duration, accompanied by oliguria. She had no frothy urine or hematuria. She did not have exertional breathlessness or orthopnea, and she had no history suggestive of a cardiac or hepatic cause of edema. She was not diabetic or hypertensive. Her rheumatoid arthritis had been diagnosed 8 months earlier, when she presented with bilateral symmetrical polyarthritis involving the small joints of her hands with significant morning stiffness of 2 hours' duration. Her rheumatoid factor was positive at a high titer. She was commenced on methotrexate 10 mg weekly and infrequent nonsteroidal anti-inflammatory drugs, with good symptom control achieved.

Her physical examination revealed that she had bilateral pitting leg edema and periorbital edema. She was not pale or icteric. No malar rash, vasculitic rash, or distal gangrene was seen. She had evidence of mild synovitis of the small joints of the hands bilaterally with no deformities. No generalized lymphadenopathy or hepatosplenomegaly was noted. Her pulse rate was 90 beats per minute; her blood pressure was 170/100 mmHg; and her jugular venous pressure was elevated to 7 cm with an undisplaced cardiac apex and normal heart sounds. A fundus examination did not reveal papilledema. Her lungs were clear with equal breath sounds bilaterally. The results of the rest of the examination were normal. Her laboratory investigation results are provided in Table [1](#Tab1){ref-type="table"}.Table 1Patient's laboratory examination resultsExaminationsResultsUrine full reportProtein 2+ Pus cells: 5--10/HPF Red blood cells: moderately full field Few granular casts presentTwenty-four-hour urinary protein excretion2 g/24 hoursDysmorphic red blood cells17%Serum creatinine2 months before presentation: 88 μmol/LOn admission: 389 μmol/LPosttreatment: 110 μmol/LSerum electrolytesSodium: 138 mmol/LPotassium: 4.1 mmol/LInflammatory markersESR: 110 mm in first hourCRP: 45 mg/dlFasting blood sugar95 mg/dlAbdominal ultrasoundNormal-sized kidneys with acute parenchymal changes and mild ascites\
No organomegalyRenal biopsyRenal parenchyma containing 20 glomeruli showing diffuse proliferative glomerular nephritis, with 14 of 20 glomeruli showing cellular crescents, and result of Congo red staining was negative\
Immune fixation not done, owing to its unavailabilityImmunological markersRheumatoid factor: high titer (120 IU/ml)ANA- and dsDNA-negativeANCA-negative (perinuclear and cytoplasmic)Complement C3: 98 mg/dl (normal range 90--180)Complement C4: 21 mg/dl (normal range 10--40)ASOT: \<200 U/mlCryoglobulins: not detectedOther secondary causes screeningHepatitis B surface antigen-negativeHepatitis C antibody-negativeHIV-1- and HIV-2-negativeMalignancy screening: negativeScreening tests done: chest x-ray, ultrasound thyroid, abdomen and pelvis, mammogram, gastrointestinal endoscopyLiver profileAlbumin: 28 g/L\
Globulin: 33 g/LTransaminases and bilirubin: normal*Abbreviations: ANA* Antinuclear antibody, *ANCA* Antineutrophil cytoplasmic antibody, *ASOT* Antistreptolysin O titer, *CRP* C-reactive protein, *dsDNA* Double-stranded deoxyribonucleic acid, *ESR* Erythrocyte sedimentation rate, *HIV* Human immunodeficiency virus, *HPF* High-power field

A diagnosis of crescentic glomerular nephritis was made. The patient was started on atorvastatin, enalapril, and diuretics. Intravenous methylprednisolone 1 g was given for 3 consecutive days, followed by 1 mg/kg oral prednisolone. She was started on intravenous cyclophosphamide 500 mg every 2 weeks for a total of six doses. She gradually had increasing urine output and was symptomatically better, with improving renal function. Her serum creatinine level was 110 μmol/L at her last clinic visit after 3 months of treatment.

Discussion {#Sec3}
==========

A middle-aged woman with seropositive rheumatoid arthritis presented to our hospital with progressively worsening generalized edema with features of intravascular volume overload. Investigations revealed a subnephrotic range of proteinuria with active sediment and impaired renal function with histological evidence of crescentic glomerular nephritis.

Because crescentic glomerular nephritis is a rare entity in rheumatoid nephropathy, we looked for other causes of crescentic glomerular nephritis. Our patient did not have clinical features of systemic vasculitis. Her antibody profile was negative for systemic lupus erythematosus, medium-vessel vasculitis, and cryoglobulinemia. Also, the result of her solid organ malignancy screening was negative. She was treated with methylprednisolone and cyclophosphamide pulses and had good recovery of her renal function.

Crescentic glomerulonephritis is a rarely described entity \[[@CR11]--[@CR13]\]. These patients generally present with microscopic hematuria, proteinuria, and renal impairment, as seen in our patient. It is usually associated with seropositive erosive disease with a median duration of arthritis of 12 years (range 1--25 years) \[[@CR11]\]. However, our patient presented within 1 year of receiving her seropositive rheumatoid arthritis diagnosis and did not have erosive arthritis. To the best of our knowledge, only one case of rheumatoid arthritis-associated ANCA-negative crescentic glomerular nephritis has been reported to date \[[@CR10]\]. Crescentic glomerular nephritis needs aggressive treatment with immunomodulators, including intravenous methylprednisolone pulses and cyclophosphamide \[[@CR14]\].

Conclusions {#Sec4}
===========

Crescentic glomerular nephritis without systemic vasculitis as an extra-articular manifestation in rheumatoid arthritis is rare but has severe clinical manifestations. Early diagnosis and treatment are vital.
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